A Dose Escalation Phase I Study of Asparec (mPEG-R-Crisantaspase) Administered as Intravenous (IV) Infusion in Patients With Relapsed or Refractory Hematological Malignancies
Latest Information Update: 11 May 2015
At a glance
- Drugs Pegcrisantaspase (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- Sponsors EUSA Pharma; Jazz Pharmaceuticals plc
- 06 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 11 Feb 2015 Planned End Date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
- 11 Feb 2015 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov record.